← Eichor
Study identifier: NCT07140744 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive Complaint

Condition: Subjective Cognitive Impairment  ·  Sponsor: Eli Lilly and Company

PhaseNA
Planned participants7000
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of the study is to measure the difference in the proportion of participants with prespecified patient management actions between a tested interventional group and a control group.

This description comes directly from the study's public registry record.

Talk to the study team

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or  ·  1-317-615-4559  ·  LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact  ·  clinical_inquiry_hub@lilly.com

Always discuss trial participation with your own doctor first.

Locations (1)

SiteRx Virtual SiteNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07140744